Benign Breast Disease

Pearlman, Mark D.; Griffin, Jennifer L.

doi:10.1097/aog.0b013e3181ee9fc7

Cited by 66 publications

(42 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3][4][5][6][7][8] Approximately 50%-80% of women in their reproductive years can express some type of fluid from the breast. 9 During the normal hormonal stimulation caused by pregnancy and breastfeeding, the mammary glands often produce physiologic discharge of milk and colostrum.…”

Section: Physiologic Dischargementioning

confidence: 99%

See 1 more Smart Citation

Management of Nipple Discharge and the Associated Imaging Findings

Patel

Falcon

Drukteinis

2015

The American Journal of Medicine

View full text Add to dashboard Cite

Section: Physiologic Dischargementioning

confidence: 99%

“…[3][4][5][6][7][8] Common causes of pathologic discharge are intraductal papilloma, duct ectasia, carcinoma, and infection. 11 Of these, the most commonly seen is a benign papilloma, identified in up to 57% of cases of pathologic nipple discharge.…”

Section: Pathologic Dischargementioning

confidence: 99%

Management of Nipple Discharge and the Associated Imaging Findings

Patel

Falcon

Drukteinis

2015

The American Journal of Medicine

View full text Add to dashboard Cite

“…In this latter group, atypical ductal or lobular hyperplasia is diagnosed in 8–10% of samples. (1) Atypia represents a high risk premalignant lesion of the breast, conveying a relative risk of approximately 4 for a later breast cancer (BC) (1–4) with a cumulative incidence of 29% at 25 years. (5–6) In proposed models of breast carcinogenesis, atypia occupies a bridging position between benign and malignant disease.…”

Section: Introductionmentioning

confidence: 99%

Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study

Hartmann

Radisky

Frost

et al. 2014

Cancer Prevention Research

205

140

View full text Add to dashboard Cite

Atypical hyperplasia is a high risk premalignant lesion of the breast, but its biology is poorly understood. Many believe that atypical ductal hyperplasia (ADH) is a direct precursor for low-grade ductal breast cancer (BC) while atypical lobular hyperplasia (ALH) serves as a risk indicator. These assumptions underlie current clinical recommendations. We tested these assumptions by studying the characteristics of the breast cancers (BCs) that develop in women with ADH or ALH. Using the Mayo Benign Breast Disease Cohort, we identified all women with ADH or ALH from 1967–2001 and followed them for later BCs, characterizing side of BC vs side of atypia; time to BC; type, histology and grade of BC, looking for patterns consistent with precursors vs risk indicators. 698 women with atypical hyperplasia were followed a mean of 12.5 years; 143 developed BC. For both ADH and ALH, there is a 2:1 ratio of ipsilateral to contralateral BCs. The ipsilateral predominance is marked in the first five years, consistent with a precursor phenotype for both ADH and ALH. For both, there is a predominance of invasive ductal cancers with 69% of moderate or high-grade. 25% are node positive. Both ADH and ALH portend risk for DCIS and invasive BCs, predominantly ductal, with two thirds moderate or high-grade. The ipsilateral breast is at especially high risk for BC in the first five years after atypia, with risk remaining elevated in both breasts long-term. ADH and ALH behave similarly in terms of later BC endpoints.

show abstract

“…[1][2][3][4] Certain benign proliferative disorders of breast can have a risk of progression to malignancy. 2,[5][6][7] Hence, thorough evaluation of breast lumps is essential.…”

Section: Introductionmentioning

confidence: 99%

Clinical radiological and pathological assessment of benign breast lumps: our institutional experience

2017

View full text Add to dashboard Cite

Background: With increased awareness about breast cancer, many women with breast lumps are attending clinics. Though benign breast lumps are most common, they may be associated with morbidity and have become cause for concern to patients. Triple assessment by clinical, radiological and pathological examination is a standard approach in the evaluation of breast lumps. Even in cases of benign breast diseases, multimodality tests are being preferred to give reassurance to patients. This study was aimed to study distribution of various benign breast lumps in relation to age at presentation, to identify sensitivity and specificity of clinical breast examination, Ultrasonography (USG) and Fine needle aspiration cytology (FNAC) methods in the evaluation of benign breast lumps and to compare with final histopathological diagnosis.Methods: A retrospective study was conducted in department of general surgery at Malla Reddy institute of medical sciences, Hyderabad from August 2013 to July 2017. 202 females with benign breast lumps were evaluated by clinical breast examination, ultrasonography (USG) and Fine needle aspiration cytology (FNAC) methods. All patients underwent excision biopsy of lump. Final histopathological report was taken as reference standard.Results: Fibroadenoma was most common in 2nd decade. Clinical breast examination and USG showed good sensitivity but less specificity than FNAC. FNAC showed both good sensitivity and specificity. There was very good degree of agreement between FNAC and histopathological diagnosis (Kappa=0.911).Conclusions: Good clinical examination can give accurate preoperative diagnosis of benign breast lumps. Triple assessment by clinical breast examination, USG and FNAC can be useful in the evaluation of benign breast lumps.

show abstract

Benign Breast Disease

Cited by 66 publications

References 28 publications

Management of Nipple Discharge and the Associated Imaging Findings

Management of Nipple Discharge and the Associated Imaging Findings

Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study

Clinical radiological and pathological assessment of benign breast lumps: our institutional experience

Contact Info

Product

Resources

About